S&P 500   4,587.68 (+0.45%)
DOW   34,535.12 (+0.15%)
QQQ   394.82 (+0.25%)
AAPL   167.81 (+1.52%)
MSFT   335.49 (+1.48%)
FB   317.07 (-2.28%)
GOOGL   2,876.71 (+1.37%)
AMZN   3,496.16 (-0.31%)
TSLA   1,135.59 (-0.80%)
NVDA   322.08 (-1.43%)
BABA   125.01 (-1.98%)
NIO   39.47 (+0.87%)
CGC   10.27 (-4.11%)
AMD   152.78 (-3.53%)
GE   94.98 (-0.01%)
MU   87.06 (+3.64%)
T   22.49 (-1.49%)
F   19.96 (+4.01%)
DIS   144.31 (-0.41%)
PFE   54.36 (+1.17%)
ACB   6.18 (-3.74%)
AMC   31.26 (-7.90%)
BA   192.86 (-2.52%)
S&P 500   4,587.68 (+0.45%)
DOW   34,535.12 (+0.15%)
QQQ   394.82 (+0.25%)
AAPL   167.81 (+1.52%)
MSFT   335.49 (+1.48%)
FB   317.07 (-2.28%)
GOOGL   2,876.71 (+1.37%)
AMZN   3,496.16 (-0.31%)
TSLA   1,135.59 (-0.80%)
NVDA   322.08 (-1.43%)
BABA   125.01 (-1.98%)
NIO   39.47 (+0.87%)
CGC   10.27 (-4.11%)
AMD   152.78 (-3.53%)
GE   94.98 (-0.01%)
MU   87.06 (+3.64%)
T   22.49 (-1.49%)
F   19.96 (+4.01%)
DIS   144.31 (-0.41%)
PFE   54.36 (+1.17%)
ACB   6.18 (-3.74%)
AMC   31.26 (-7.90%)
BA   192.86 (-2.52%)
S&P 500   4,587.68 (+0.45%)
DOW   34,535.12 (+0.15%)
QQQ   394.82 (+0.25%)
AAPL   167.81 (+1.52%)
MSFT   335.49 (+1.48%)
FB   317.07 (-2.28%)
GOOGL   2,876.71 (+1.37%)
AMZN   3,496.16 (-0.31%)
TSLA   1,135.59 (-0.80%)
NVDA   322.08 (-1.43%)
BABA   125.01 (-1.98%)
NIO   39.47 (+0.87%)
CGC   10.27 (-4.11%)
AMD   152.78 (-3.53%)
GE   94.98 (-0.01%)
MU   87.06 (+3.64%)
T   22.49 (-1.49%)
F   19.96 (+4.01%)
DIS   144.31 (-0.41%)
PFE   54.36 (+1.17%)
ACB   6.18 (-3.74%)
AMC   31.26 (-7.90%)
BA   192.86 (-2.52%)
S&P 500   4,587.68 (+0.45%)
DOW   34,535.12 (+0.15%)
QQQ   394.82 (+0.25%)
AAPL   167.81 (+1.52%)
MSFT   335.49 (+1.48%)
FB   317.07 (-2.28%)
GOOGL   2,876.71 (+1.37%)
AMZN   3,496.16 (-0.31%)
TSLA   1,135.59 (-0.80%)
NVDA   322.08 (-1.43%)
BABA   125.01 (-1.98%)
NIO   39.47 (+0.87%)
CGC   10.27 (-4.11%)
AMD   152.78 (-3.53%)
GE   94.98 (-0.01%)
MU   87.06 (+3.64%)
T   22.49 (-1.49%)
F   19.96 (+4.01%)
DIS   144.31 (-0.41%)
PFE   54.36 (+1.17%)
ACB   6.18 (-3.74%)
AMC   31.26 (-7.90%)
BA   192.86 (-2.52%)
NASDAQ:FUSN

Fusion Pharmaceuticals Stock Forecast, Price & News

$5.80
-0.17 (-2.85%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.70
$6.10
50-Day Range
$5.77
$8.86
52-Week Range
$5.69
$13.69
Volume
21,385 shs
Average Volume
48,588 shs
Market Capitalization
$249.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.07
30 days | 90 days | 365 days | Advanced Chart
Receive FUSN News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Fusion Pharmaceuticals logo

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FUSN
Fax
N/A
Employees
61
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$7.06 per share

Profitability

Net Income
$-78.33 million
Pretax Margin
-8,812.88%

Debt

Price-To-Earnings

Miscellaneous

Free Float
40,430,000
Market Cap
$249.78 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/24/2022

MarketRank

Overall MarketRank

2.24 out of 5 stars

Medical Sector

336th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

52nd out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -












Fusion Pharmaceuticals (NASDAQ:FUSN) Frequently Asked Questions

Is Fusion Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fusion Pharmaceuticals stock.
View analyst ratings for Fusion Pharmaceuticals
or view top-rated stocks.

When is Fusion Pharmaceuticals' next earnings date?

Fusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Fusion Pharmaceuticals
.

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.58) by $0.13. The company earned $0.33 million during the quarter.
View Fusion Pharmaceuticals' earnings history
.

What price target have analysts set for FUSN?

4 Wall Street analysts have issued 1 year price objectives for Fusion Pharmaceuticals' stock. Their forecasts range from $17.00 to $19.00. On average, they anticipate Fusion Pharmaceuticals' stock price to reach $18.00 in the next year. This suggests a possible upside of 210.3% from the stock's current price.
View analysts' price targets for Fusion Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Fusion Pharmaceuticals' key executives?

Fusion Pharmaceuticals' management team includes the following people:
  • Dr. John F. Valliant, Founder, CEO & Director (Age 51, Pay $845.5k)
  • Mr. John J. Crowley CPA, Chief Financial Officer (Age 47, Pay $646.43k)
  • Dr. Eric Burak, Chief Scientific Officer (Age 56, Pay $600.78k)
  • Dr. James J. O'Leary, Chief Medical Officer (Age 56, Pay $537.64k)
  • Ms. Lynn Wick, Exec. Director of Fin. & Operations
  • Ms. Amanda Cray, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Maria D. Stahl, Chief Legal Officer (Age 50)
  • Dr. Marc Schwabish Ph.D., SVP of Bus. Devel. and US Operations
  • Dr. Isabelle Dussault Ph.D., Sr. VP of Research

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).

When did Fusion Pharmaceuticals IPO?

(FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Fusion Pharmaceuticals' stock symbol?

Fusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "FUSN."

Who are Fusion Pharmaceuticals' major shareholders?

Fusion Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Johnson & Johnson (8.52%), Point72 Asset Management L.P. (1.99%), BlackRock Inc. (0.96%), Victory Capital Management Inc. (0.62%), Morgan Stanley (0.19%) and Sectoral Asset Management Inc (0.09%). Company insiders that own Fusion Pharmaceuticals stock include Adams Street Partners Llc, Johnson & Johnson and Steven Gannon.
View institutional ownership trends for Fusion Pharmaceuticals
.

Which major investors are selling Fusion Pharmaceuticals stock?

FUSN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., and Victory Capital Management Inc..
View insider buying and selling activity for Fusion Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Fusion Pharmaceuticals stock?

FUSN stock was bought by a variety of institutional investors in the last quarter, including Johnson & Johnson, Sectoral Asset Management Inc, Millennium Management LLC, Morgan Stanley, Geode Capital Management LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Fusion Pharmaceuticals stock in the last two years include Johnson & Johnson, and Steven Gannon.
View insider buying and selling activity for Fusion Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fusion Pharmaceuticals' stock price today?

One share of FUSN stock can currently be purchased for approximately $5.80.

How much money does Fusion Pharmaceuticals make?

Fusion Pharmaceuticals has a market capitalization of $249.78 million. The company earns $-78.33 million in net income (profit) each year or ($1.82) on an earnings per share basis.

How many employees does Fusion Pharmaceuticals have?

Fusion Pharmaceuticals employs 61 workers across the globe.

What is Fusion Pharmaceuticals' official website?

The official website for Fusion Pharmaceuticals is fusionpharma.com.

Where are Fusion Pharmaceuticals' headquarters?

Fusion Pharmaceuticals is headquartered at 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6.

How can I contact Fusion Pharmaceuticals?

Fusion Pharmaceuticals' mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The company can be reached via phone at 289-799-0891 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.